Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Ming-yi Hu"'
Publikováno v:
The Journal of Clinical Endocrinology and Metabolism
Context The ACTIVE study demonstrated the antifracture efficacy of abaloparatide in postmenopausal women with osteoporosis. ACTIVExtend demonstrated sustained fracture risk reduction with alendronate in abaloparatide-treated participants from ACTIVE.
Autor:
Ming Yi Hu, Nancy E Lane, Carol Zapalowski, Andrea Singer, Gary Hattersley, Benjamin Z. Leder, Robin K. Dore
Publikováno v:
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, vol 34, iss 12
Journal of Bone and Mineral Research
Journal of Bone and Mineral Research
In the randomized, placebo-controlled, double-blind phase 3 ACTIVE study (NCT01343004), 18 months of abaloparatide 80 μg daily (subcutaneous injection) in postmenopausal women at risk of osteoporotic fracture significantly reduced the risk of verteb
Autor:
Andi Leubitz, Kate Banks, Kaela M. Porter, Frederic Vanhoutte, Ming‐yi Hu, Kathleen Campbell, Kathleen Tencer, Tom Haverty, Efrat Gordon
Publikováno v:
Clinical Pharmacology in Drug Development
ELX‐02 is an investigational compound being developed as a therapy for genetic diseases caused by nonsense mutations such as cystic fibrosis. Structurally, ELX‐02 is an aminoglycoside analogue that induces read‐through of nonsense mutations thr
Autor:
Ming-yi Hu, Jean-Yves Reginster, Gregory C. Williams, Gary Hattersley, E. Michael Lewiecki, Lorraine A. Fitzpatrick
Publikováno v:
Calcified Tissue International
Abaloparatide (ABL) is a 34-amino acid peptide designed to be a selective activator of the parathyroid hormone receptor type 1 signaling pathway. In the Abaloparatide Comparator Trial In Vertebral Endpoints (ACTIVE), subcutaneous ABL reduced the risk
Autor:
John P. Bilezikian, Ming-yi Hu, Lorraine A. Fitzpatrick, Claus Christiansen, Bente Juel Riis, Felicia Cosman, Gregory C. Williams, Paul D. Miller, Gary Hattersley, Dennis M. Black, Ivo Valter
Publikováno v:
Mayo Clinic Proceedings. 92:200-210
Objective To assess the efficacy and safety of 18 months of subcutaneous abaloparatide (ABL-SC) or placebo (PBO) followed by 6 months of alendronate (ALN) (preplanned interim analysis). Patients and Methods ACTIVExtend, an extension of ACTIVE, enroll
Autor:
Lorraine A. Fitzpatrick, Ming-yi Hu, Gregory C. Williams, Gary Hattersley, Dennis M. Black, Felicia Cosman
Publikováno v:
Journal of Bone and Mineral Research. 32:17-23
Abaloparatide-SC is a novel 34-amino acid peptide created to be a potent and selective activator of the parathyroid hormone receptor type 1 (PTHR1) signaling pathway. In the Abaloparatide Comparator Trial in Vertebral Endpoints (ACTIVE) Phase 3 trial
Publikováno v:
Archives of Osteoporosis
Summary We evaluated the efficacy of abaloparatide in women who were at increased risk for fracture, based on CHMP recommended risk thresholds, at the Abaloparatide Comparator Trial In Vertebral Endpoints (ACTIVE) study baseline. Among patients at hi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::70f73db21d977923f53430bf5521a154
https://acuresearchbank.acu.edu.au/item/8774x/effect-of-abaloparatide-on-vertebral-nonvertebral-major-osteoporotic-and-clinical-fractures-in-a-subset-of-postmenopausal-women-at-increased-risk-of-fracture-by-frax-probability
https://acuresearchbank.acu.edu.au/item/8774x/effect-of-abaloparatide-on-vertebral-nonvertebral-major-osteoporotic-and-clinical-fractures-in-a-subset-of-postmenopausal-women-at-increased-risk-of-fracture-by-frax-probability
Autor:
John P. Bilezikian, Paul D. Miller, Robin K. Dore, Ming-yi Hu, Henry G. Bone, Bruce H. Mitlak, Gary Hattersley, Felicia Cosman, Kenneth G. Saag, S. Papapoulos, Gregory C. Williams, Lorraine A. Fitzpatrick, René Rizzoli
Publikováno v:
Journal of Clinical Endocrinology and Metabolism, Vol. 103, No 8 (2018) pp. 2949-2957
Journal of Clinical Endocrinology and Metabolism, 103(8), 2949-2957
The Journal of Clinical Endocrinology and Metabolism
Journal of Clinical Endocrinology and Metabolism
Journal of Clinical Endocrinology and Metabolism, 103(8), 2949-2957
The Journal of Clinical Endocrinology and Metabolism
Journal of Clinical Endocrinology and Metabolism
Purpose In women with postmenopausal osteoporosis, we investigated the effects of 24 months of treatment with alendronate (ALN) following 18 months of treatment with abaloparatide (ABL) or placebo (PBO). Methods Women who completed ABL or PBO treatme
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e451ea3a508f7e5afc2d4d5a1fa218d2
https://doi.org/10.1210/jc.2018-00163
https://doi.org/10.1210/jc.2018-00163
Autor:
Edith M. C. Lau, Paul D. Miller, Lorraine A. Fitzpatrick, Ming-yi Hu, Gregory C. Williams, Luis A. Russo, Bente Juel Riis, C. Christiansen, Gary Hattersley, Alan G. Harris
Publikováno v:
Bone. 120
Abaloparatide is a 34-amino acid peptide that selectively binds to the RG conformation of the parathyroid hormone receptor type 1. It was developed for the treatment of women with postmenopausal osteoporosis at high risk of fracture. In ACTIVE, an 18
Autor:
Gary Hattersley, Gregory C. Williams, Dennis M. Black, Lorraine A. Fitzpatrick, Felicia Cosman, Ming-yi Hu
Publikováno v:
Journal of Clinical Densitometry. 21:28
Abaloparatide-SC is a novel 34-amino acid peptide created to be a potent and selective activator of the parathyroid hormone receptor type 1 (PTHR1) signaling pathway. In the Abaloparatide Comparator Trial in Vertebral Endpoints (ACTIVE) Phase 3 trial